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Although continuous hepatic artery infusions (CHAI) of (FUDR) Floxuridine have been effective in
reducing the size of colorectal hepatic metastases the toxicity of the infusions have been high with almost
a quarter of the patients developing biliary sclerosis. Techniques to lower toxicity, yet continue the
beneficial antitumor effects, are being investigated. One suggested strategy is to change the flow pattern
of the continuous infusion from a constant rate to a day cycled pattern. In this infusion a continuous rate
is given over a 24 hour period with 60% of the infusion delivered between 3 PM and 9 PM and the least
amount of infusion delivered between 3 AM and 9 PM. Previous research has suggested that this day
cycle pattern will lower the toxicity of the infusion. This experiment is a test of "day cycled" continuous
hepatic artery infusions in rats bearing hepatic metastases from a colon adenocarcinoma. Previous
research from our laboratory has shown a lowered toxicity when the constant infusion was replaced with
the day cycled pattern.
In the present study 10 rats with hepatic adenocarcinoma metastases were placed on constant CHAI
of FUDR at 10mg/kg/day for 14 days. There was an 80% mortality from chemotherapy toxicity and a
90% objective response rate. Nine other rats were treated with "day cycled" CHAI ofFUDR at 15mg/
kg/d. There was no mortality in this group and the objective response rate was 90% as in the previous
group. This study demonstrated that "day cycled" CHAI ofFUDR was substantially less toxic and that
the antitumor effect was identical to the constant infusion.
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INTRODUCTION
Continuous hepatic artery infusions (CHAI) of floxuridine (FUDR) through an
implantable pump was popularized as a treatment for hepatic metastases from
colorectal cancer in the early 1980s. Although there was a wave of initial enthu-
siasm, this began to die down as it became clear that there were substantial
toxicities that accompanied the significant benefits seen with this mode of therapy.
The most serious of the toxicities, biliary sclerosis, also known as sclerosing
cholangitis, is a fibrosis of the bile ducts, usually at the hepatic duct bifurcation,
seen mainly in patients who were responders to therapy1. Several modifications of
the treatment have been tried to see if toxicity could be reduced, including a
reduction of the dose of chemotherapy and the addition of Decadron to the
23 infusion’. Both of these modifications helped somewhat but didn’t get rid of the
problem.
Address correspondence to: M. Margaret Kemeny, M.D., F.A.C.S., Chief, Surgical Oncology, St.
Vincent’s Hospital, 153 West llth St., New York 10011, USA.
219220 M.M. KEMENY ET AL.
Recently interest has grown for the idea of circadian patterning of the continuous
infusion which might reduce the toxic effect of chemotherapy on normal liver and
have an equal effect on the tumor cells as the constant continuous infusion. These
hypotheses have not been tested in an experimental model using hepatic artery
infusion. This experiment is a test in a rat model of the efficacy of CHAI of
floxuridine (FUDR) with circadian patterning against established liver metastases.
MATERIALS AND METHODS
Animals
Fisher rats were kept in the St. Vincent’s Medical Center animal facility. They were
fed ad lib on a diet of rat chow. The lighting was set to a routine of 8 a.m. to 8 p.m.
lights on and 8 p.m. to 8 a.m. lights off.
Tumor
A colon adenocarcinoma line (dinitrobenzene induced colon cancers purchased
from the National Cancer Institute) was passaged in Fisher rats using a subcuta-
neous injection into the hind quarter of animals. When the tumor was palpable and
over 3 cm in size it was felt to be ready for use in the experiments. Rats were
sacrificed and the tumor was resected surgically. It was then sterilely minced into
small pieces and passed through a number 40 screen. The tumor was then placed in
RPMI media with streptomycin and penicillin and washed three times. Tumor was
resuspended in Hanks Basic Salt Solution to a volume of 1 cc. This slurry of cells
was then used for injection (1 107 cells/cc). The rats were given general
anesthesia with use of Ketamine (Ketalar-Parke Davis) 45 mg/kg mixed with
Droperidol 0.1 mg/kg by intra muscular injection. A right lateral subcostal incision
was used to enter the peritoneum. The right lobe of the liver was pulled out into the
wound and a subcapsular injection of 0.1cc of the cell slurry mentioned above was
injected. A swab of collodium was placed over the injection site to seal the needle
puncture wound. The liver was then pushed back into the peritoneum and the
abdomen was closed with staples. Ten days after implantation of tumor into the
liver a midline laparotomy was done. At the time of this laparotomy the liver tumor
was measured. An established tumor had to be measurable in 3 dimensions for the
rat to be used for the experiment.
Placement of the Arterial Catheter
Ten days after tumor implantation each rat underwent a laparotomy for placement
of a PE-10 Polyethylene tube (Clay Adams) for hepatic artery infusion. At that
time the liver tumor was measured before going ahead with the catheterization.
The average rat was 250 gm at the time of the operation and eight weeks old. The
catheter was placed into the gastroduodenal artery and th artery was ligated
distally. The catheter was then passed through the abdominal fascia, tunnelled
under the skin to an opening between the scapulae. At that spot a metal button was
placed subcutaneously with a coiled metal catheter attached (Instatech). The PE
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to a swivel placed above the rat’s cage. This swivel was connected to the infusion
pump. This arrangement allowed the rat free mobility in its cage, as well as
protecting the button apparatus. For additional protection a small jacket was
placed on the rat, preventing it from chewing on the catheter exit site.
The portable Intelliject pumps were used for the infusions because of their
programmability for a varied infusion cycle. The accuracy of flow rates were
verified before use.
Ten animals were placed on a constant infusion cycles and 9 on a "day cycled"
infusion. The infusions were continuous for 14 days. After the 14 day infusion
heparinized saline was infused for an additional 14 days. Then the animals were
sacrificed, their livers were removed, the hepatic tumors were measured in 3
dimensions and the livers were sent to pathology.
Infusion Schedules
Rats given the constant CHAI received 4cc/day ofFUDR (Roche) at 10 mg/kg/day.
Rats on the "day cycle" infusion received 4cc/day of FUDR at 15mg/kg/day. The
delivery dose was as follows (Figure 1):
From 9AM to 3PM 0.6 cc (.lcc/hr)
From 3PM to 9PM 2.7 cc (.45cc/hr)
From 9PM to 3AM 0.6 cc and
From 3AM to 9AM 0.08 cc (.013 cc/hr).
All experiments were approved by the Animal Welfare Committee of St.
Vincent’s Hospital in accordance to the guidelines of the Public Health Service
Policy of Humane Care and Use of Laboratory Animals.
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RESULTS
Ten rats were given a constant FUDR infusion of 10 mg/kg/d for 14 days. Infusions
were started 10 days after hepatic implantation of adenocarcinoma. The ,mean
tumor volume at the time of laparotomy for catheter placement was 1022 +
138mm3. All 10 animals had a decrease in tumor volume as a result of the infusion.
The post infusion mean volume was 68.2 + 26.6mm3. Eight of the animals died of
infusion toxicity prior to the end of the 30 day period. The 2 remaining animals
survived the 30 day period. The mean survival for the 8 animals who died was 14.95
+ 4.74 days.
Nine rats were given a CHAI of FUDR with a day cycle circadian pattern at 15
mg/kg/d. All of these animals survived the 14 day infusion and 14 day rest period.
Eight rats had a reduction in tumor and one had no change. The mean tumor
volume pre infusion was 1202 + 371 mm and the mean post infusion volume was
34.78 + 19.8 mm3. There was no statistically significant difference in response
between the constant infusion group or the circadian patterned infusion group
(Figure 2).
PATHOLOGY
The livers were fixed in 10% buffered formalin. All livers were sectioned at 3 mm
intervals and no less than 2 blocks were submitted per case for paraffin sections. A
minimum 4 cm2 of cross sectional area per case was examined using standard
hematoxylin/eosin staining.
The livers from the rats with the constant infusion FUDR contained necrotic
tumor in most cases with focal but widespread centrilobular necrosis of the hepatic
parenchyma. The specimens from the animals treated with the circadian rhythm
patterns had limited focal necrosis of the hepatic parenchyma. The tumors were
necrotic and similar in appearance to the constant infusion group.
DISCUSSION
The use of circadian rhythm for timing the infusions of chemotherapy is gaining
acceptance with some of the recent studies on intravenous chemotherapy. A study
reported this year at ASCO cited a 58% response rate in patients who had
metastases from colorectal cancer when their intravenous chemotherapy was
modulated by a circadian rhythm pattern4. This response rate was even more
remarkable since most of the patients had failed other chemotherapy regimens.
Other studies have shown that in rats a continuous FUDR intravenous infusion is
given with the majority of the daily infusion delivered from 3PM to 9PM and the
least delivered from 3AM to 9AM is less toxic than a constant continuous infusion5.
The concept of decreased toxicity with a "day cycle" circadian patterned con-
tinuous infusion has been utilized clinically for CHAI of FUDR for hepatic
metastases from colorectal primaries5. These studies suggest that toxicity is lowered
by using a circadian timed infusion and that antitumor efficacy is not compromised.
In our laboratory we have developed an animal model that utilizes continuous
hepatic artery infusions (CHAI) for prolonged periods of time (one month orHEPATIC ARTERY INFUSION 223
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longer) in rats. Using this model we have previously reported on toxicity experi-
ments with CHAI of FUDR6. In the previously done experiments rats given
constant CHAI of FUDR at 15 mg/kg/d all died at 9.3 days + 1.7 SD. The rats
given a circadian patterned CHAI ofFUDR at 15 mg/kg/d, with the majority of the
daily dose given between 3PM and 9PM (what we call a "day cycle" pattern), all
survived the infusion with minimal pathological hepatic toxicity. When the infusion
was given with a "night cycle" pattern, that is most of the infusion was given
between 9PM and 3AM, it was more toxic with all animals dying at a mean of 5.5
days + 1.2 SD.
Using these results we went ahead to test the efficacy of circadian infusions
against established metastatic colon adenocarcinomas transplanted into the liver.
In these present experiments we have shown that day cycled infusions allow more
FUDR to be given with lower toxicity and an equal antitumor effect. More
specifically 15 mg/kg/d of FUDR was administered for a 14 day CHAI with no
toxicity versus an 80% toxicity when 10 mg/kg/day were given using a constant
CHAI pattern.
The timing of the "day cycle" was picked because of the previous work by
Hrushevsky. The mechanism for the decreased toxicity is unknown but various
hypotheses have been proposed. It is known that when 5FU is given with a
continuous intravenous infusion the concentration of the drug in the blood varies
with time during a 24 hour period7. It was discovered that the highest concentra-
tions were at night. The mechanism for FU metabolism is mainly centered in the
liver. Thus it seems that hepatic metabolism of this drug is higher during the day.
This increase in hepatic metabolism during daylight hours may explain the results
of the present experiment. With increased metabolism of the drug during the time
of greatest exposure (during the day) the systemic toxicities would be decreased.
Because it is a regional infusion the tumor cells are being exposed to the FUDR at224 M.M. KEMENY ET AL.
higher doses before it has been metabolized so the antitumor effect is not
compromised by the increased metabolism.
Other variations known to occur with a circadian pattern include increased
corticosteroid levels in the late afternoon (in rats)a, increased T lymphocyte release
(at night), increased CD4 cell activation (in afternoon), and increased antigen
recognition and destruction (in the morning)9. These changes might also effect
toxicity and tumor response in a circadian pattern.
Further work should be done to ascertain if the present "day cycle" circadian
schedule is the best one for decreasing toxicity and if it is also the optimal one for
antitumor effect. When these criteria have been worked out this modality will be
ready to enter the clinical arena.
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